Contact Us

ORGANOIDSCIENCES Overview

Establishing a research hub for technology advancement while expanding production and marketing capabilities worldwide

GMP Infrastructure for Organoid-Based Regenerative Therapies

Ensuring stable production and supply through a dedicated GMP facility

Gwangmyeong GMP Center

  • Located within SK Technopark in Gwangmyeong
  • Rapid facility setup through acquisition of an existing cell therapy GMP facility
  • Renovated and optimized for organoid-based production
  • Total area: 825 m² (approx. 250 pyeong) with 4 manufacturing suites and a fully equipped quality control room
  • Obtained GMP manufacturing license and cell processing facility approval in Q4 2022

Asan Medical Center GMP Center (Seoul)

  • Located within the Biomedical Research Institute at Asan Medical Center
  • R&D collaboration agreement signed with Asan Medical Center in June 2021
  • Planned area: 560 m² (approx. 170 pyeong) with 2 manufacturing suites and a QC lab (under construction)
  • Construction scheduled to begin in April 2025, with completion expected by October 2025
  • Backed by Asan Foundation investment through Series A2 and B funding rounds

Core Peoples

Composed of C-Level executives and advisors, each an expert in their respective fields (R&D, operations, commercialization, management) with 10-30 years of experience with excellence

Jong-Man Yoo

Founder & CEO (M.D., Ph.D.)
  • MD,PhD, CHA University Medical School (2014)
  • Associate Professor , CHA University Medical School (2015 ~ )
  • Director ,CHA Group Organoid Center (2017~)
  • Head, Medical Division at CHA Biotech (2018~2022)
  • Director & Founder, Organoid Society (2018~2022)
  • CEO, ORGANOIDSCIENCE (2018~)
  • Head of the 3D Biological Tissue Platform Project Group, Ministry of Trade, Industry and Energy (2020 ~ )

Dr. Kyung-Jin Lee

CTO (총경력 13년)
Head of R&D, Managing Director Overall R&D of fundamental technologies
Vice Center Director, Organoid Research Center, Cha Group Comprehensive Research Institute

Dr. Dong-Yeon Hwang

CSO (총경력 35년)
Chief Scientific Officer, Senior Managing Director Efficacy/evaluation model & analysis method development
Assistant Professor, Harvard Medical School

Dr. Hyun-Soo Shin

CMO (총경력 35년)
Chief Medical Officer, Senior Managing Director R&D of core and applied technologies
Head, Department of Radiation Oncology, Bundang CHA Hospital

Yong-Seok Lee

Head of Manufacturing Headquarters
Executive Managing Director, Head of Manufacturing Strategy, CDMO, and Quality Management
  • Executive Managing Director, Cell and Gene Therapy Center, CellabMED Inc.
  • Director, Recombinant Protein Division, Manufacturing Headquarters, GC Biopharma

Eun-Joo Bae

Head of RGB Research Institute

Executive Vice President, Head of RGB Research
Oversees Bio-Convergence Technology and Innovation of Research Infrastructure

  • Former Dean, College of Pharmacy, Chonbuk National University
  • Adjunct Professor, Chonbuk National University Hospital

Jin-Man Hong

CFO (총경력 14년)
Head of Finance, Managing Director
Overall management of management, finance, and personnel
  • Chief Financial Officer (CFO), JLK
  • Chief Operating Officer (COO), Docple

Mi-Young Son

Ph.D.
Advisory on organoid R&D Advisory on the enhancement of new material evaluation solutions
Center Director, Stem Cell Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology

Byeong-Deok Ye

M.D. / Ph.D.
Advisory on organoid R&D Advisory on the enhancement of new material evaluation solutions
Director, Inflammatory Bowel Disease Center, Seoul Asan Medical Center

Beom-Jae Lee

M.D. / Ph.D.
Advisory on ATORM-C development Clinical trial protocol development and clinical PI
Conducting advanced regenerative medicine clinical research on ATORM-C

Jean–Frederic Colombel

M.D. / Ph.D.
ATORM-C North American clinical design US clinical trial PI, KOL and infrastructure provision
President, International Organization for Inflammatory Bowel Diseases (IOIBD)

Stefan Schreiber

M.D. / Ph.D.
ATORM-C European clinical design
EU clinical trial PI, KOL and infrastructure provision
Director of Internal Medicine, Kiel Univ Germany

History

Certifications, Awards & Patents

Year Certifications, Awards & Patents

  • 2018Established ORGANOIDSCIENCES
  • 2020Completed Series A investment (KRW 8 billion)
  • 2021Secured Series B investment (KRW 41 billion)
  • 2022ATORM-C, Approval for Clinical Trial of Advanced Regenerative Medicine
  • 2022Established joint venture PODO Therapeutics with Severance Hospital
  • 2023ATORM-COrganoid therapy certified as ATMP by EMA

Year Certifications, Awards & Patents

  • 2023First Patient Treatment of ATORM-C  in Advanced Regenerative Medicine
  • 2023Established VOS DISCOVERY and Partnership  Lambda Biologics GmbH
  • 2024Certified as “National Advanced Strategic Technology” company
  • 2024Selected as a "Pre-Unicorn 2024" by the Ministry of SMEs
  • 2025Received the Prime Minister’s Award on National Invention Day
  • 2025Approved for KOSDAQ listing under special technology exception
  • Commissioned by the Ministry of Food and Drug Safety (MFDS) to develop guidelines for organoid-based regenerative therapies (2023–2025)
  • Selected as one of Forbes Korea’s Top 50 Bio Companies in 2024
  • Ranked 3rd globally in the number of registered organoid-related patents
  • Published organoid-related research with a cumulative impact factor (IF) of 135
  • Awarded over KRW 30 billion in national R&D funding
  • Commissioned by MFDS for organoid standardization and biobank development (2024–2028)
  • First in Korea to register and treat patients with organoid-based regenerative therapy (2023)

Toward a Sustainable Future
with ORGANOIDSCIENCES

Join ORGANOIDSCIENCES in leading groundbreaking organoid research and the advancement of next-generation cell therapies.
Be part of the journey of biomedical innovation that is shaping the future of healthcare.

Technical Inquiry

bd@organoidrx.com

PR/Marketing inquiry

pr@organoidrx.com

Recruitment inquiry

hr.admin@organoidrx.com

General Inquiry

info@organoidrx.com